Literature DB >> 22503308

Trimming the fat with an IVIG approval process.

Signy Chow, Giselle Salmasi, Jeannie L Callum, Yulia Lin.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22503308     DOI： 10.1016/j.transci.2012.03.030

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


× No keyword cloud information.
  4 in total

1.  Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders.

Authors:  Rohan Ameratunga
Journal:  Allergy Asthma Clin Immunol       Date:  2017-12-06       Impact factor: 3.406

2.  Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease.

Authors:  Khanh-Van Y Van Anh; Saloni Shah; Adriana H Tremoulet
Journal:  Front Pediatr       Date:  2020-04-03       Impact factor: 3.418

3.  Evaluation and enhancement of standard equations for renal function estimation in individuals with components of metabolic disease.

Authors:  Luigi Brunetti; Hyunmoon Back; Sijia Yu; Urma Jalil; Leonid Kagan
Journal:  BMC Nephrol       Date:  2021-11-22       Impact factor: 2.388

4.  Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.

Authors:  Willem Jan R Fokkink; Sander J van Tilburg; Brenda C M de Winter; Sebastiaan D T Sassen; Pieter A van Doorn; Birgit C P Koch; Bart C Jacobs
Journal:  Clin Pharmacokinet       Date:  2022-07-04       Impact factor: 5.577
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.